Sharing Expertise in Vaccine Innovation

Since the early 2000s, BioNet has been a catalyst for global vaccine access and a leader in advancing vaccine technology and innovation.

Specializing in the development and manufacturing of genetically engineered vaccines, BioNet is the world’s sole producer of licensed next-generation recombinant pertussis vaccines. This breakthrough marks the first introduction of a new pertussis vaccine in over 20 years, contributing to address the global resurgence of pertussis cases.

Building on this legacy, BioNet is also pioneering next-generation vaccines through its proprietary mRNA technology platform, driving the development of innovative solutions to meet critical public health challenges.

With expertise spanning the entire vaccine lifecycle, BioNet’s team of over 200 professionals is committed to delivering high-quality vaccines to combat re-emerging and pandemic diseases. Headquartered in Bangkok, Thailand, and Lyon, France, BioNet also operates business and operational teams in the United States and Australia, ensuring a global impact.

Vision

To be a leading biotech organization, driving innovation and sharing expertise to ensure equitable access to vaccines worldwide.

Mission

“Our dream is a world free from preventable diseases.
Our mission is to make this dream a reality.”

Quality Policy

BioNet commits to develop and manufacture innovative high-quality vaccines that comply with applicable regulatory requirements.

Committed to Excellence

At BioNet, we are dedicated to developing and manufacturing innovative, high-quality vaccines that meet and exceed regulatory requirements. Our commitment to excellence is reflected in our continuous pursuit of quality beyond compliance, ensuring that both our products and processes adhere to the highest standards through ongoing improvements to our quality systems.